Aim: The inflammatory process plays an important role in cardiovascular diseases. Therefore, many markers have been used to detect the inflammatory process. It has been reported that neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) can be used to detect the inflammatory process in patients with deep vein thrombosis. In this study, we aim to investigate whether NLR and PLR values change as a result of different deep vein thrombosis treatment protocols.
Material and Methods: A total of 84 patients, 51 male and 33 female were included in the study. The mean age of the participants was 56.32±12.87. The patients were divided into three groups: the control group (group 1), the group treated with warfarin (group 2), and the group treated with rivaroxaban (group 3).
Results: The results of the analysis obtained at the time of the detection of deep vein thrombosis were compared with the results of the blood tests performed in the first month after the treatment.
In patients with deep vein thrombosis, white blood cell, neutrophil, and eosinophil values, as well as NLR and PLR values were found to be higher than the individuals in the control group. After one month of different deep vein thrombosis treatment protocols, there was no significant difference between group 2 and group 3 in terms of NLR and PLR values.
Conclusion: It has been observed that NLR and PLR values increase as a reflection of the inflammatory process after deep vein thrombosis. However, no significant change was observed in NLR and PLR values with rivaroxaban and warfarin treatments, and it was concluded that these two markers may not be suitable for following the inflammatory process.
Key words: Deep vein thrombosis, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, inflammation
|
